-
公开(公告)号：US5834599A
公开(公告)日：1998-11-10
申请号：US26276
申请日：1993-03-04
申请人： Tse-Wen Chang , Sek C. Fung , Cecily Rou-Yun Sun , Bill Nai-Chau Sun , Nancy T. Chang , Young Woo Kim
发明人： Tse-Wen Chang , Sek C. Fung , Cecily Rou-Yun Sun , Bill Nai-Chau Sun , Nancy T. Chang , Young Woo Kim
CPC分类号： A61K47/48469 , A61K38/00 , C07K2317/24
摘要： Monoclonal antibodies are revealed which bind to the gp 120 protein on the envelope of HIV-1. These antibodies neutralize HIV-1. They inhibit the infection of T cells, and also inhibit syncytium formation. Further, the antibodies are group-specific and neutralize different strains and isolates of HIV-1. These antibodies have a variety of uses, including the treatment and prevention of AIDS and ARC. The antibodies are used in immunotoxins which are specifically toxic to HIV-1 infected T cells.
摘要翻译： 揭示单克隆抗体结合HIV-1包膜上的gp120蛋白。 这些抗体中和HIV-1。 它们抑制T细胞的感染，并抑制合胞体的形成。 此外，抗体是组特异性的，并且中和HIV-1的不同菌株和分离株。 这些抗体具有各种用途，包括治疗和预防艾滋病和ARC。 该抗体用于对HIV-1感染的T细胞特异性毒性的免疫毒素中。
-
公开(公告)号：US08637637B2
公开(公告)日：2014-01-28
申请号：US12657004
申请日：2010-01-12
IPC分类号： C07K17/00
CPC分类号： C07K14/61 , C07K2319/30
摘要： Fc fusion proteins of human growth hormone with good biological activities relative to rhGH on a molar basis are disclosed. The hGH-L-vFc fusion protein comprises hGH, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such hGH-L-vFc fusion proteins exhibit extended or prolonged serum half-life and/or good biological activities relative to that of rhGH on a molar basis, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time.
摘要翻译： 公开了以摩尔计相对于rhGH的具有良好生物活性的人生长激素的Fc融合蛋白。 hGH-L-vFc融合蛋白包含hGH，约20个或更少氨基酸的柔性肽接头和人IgG Fc变体。 Fc变体具有非溶解性质并且显示出最小的不期望的Fc介导的副作用。 还公开了以高表达水平制备或产生这种融合蛋白的方法。 这样的hGH-L-vFc融合蛋白在摩尔基础上相对于rhGH显示出延长的或延长的血清半衰期和/或良好的生物活性，导致改善的药代动力学和药效学，因此在一段时间内将需要更少的注射 。
-
公开(公告)号：US20120219547A1
公开(公告)日：2012-08-30
申请号：US13405144
申请日：2012-02-24
申请人： Baoguo Zhu , Desheng Tao , Bill Nai-Chau Sun , Lee-Hwei King Sun , Ruey Shyan Liou , Cecily Rou-Yun Sun , Qiang Li , Yucai Peng , Jingwei Zhang , Zhenxiang Hu
发明人： Baoguo Zhu , Desheng Tao , Bill Nai-Chau Sun , Lee-Hwei King Sun , Ruey Shyan Liou , Cecily Rou-Yun Sun , Qiang Li , Yucai Peng , Jingwei Zhang , Zhenxiang Hu
IPC分类号： A61K39/395 , C12N15/13 , A61P35/00 , A61P37/06 , C12N5/10 , A61P33/06 , A61P37/00 , A61P31/22 , A61P11/00 , C12N15/63 , C07K16/24 , A61P31/04
CPC分类号： C07K16/241 , A61K2039/505 , C07K2317/24 , C07K2317/76 , C07K2317/92 , Y02A50/412
摘要： The present invention provides a humanized anti-TNF monoclonal antibody and the use thereof. The humanized anti-TNF monoclonal antibody significantly reduces the immunogenicity of murine-antibody while retaining the ability of antibody to recognize antigen, compared with conservative mouse chimeric antibody. Therefore, safety of the antibody in clinical applications has been improved.
摘要翻译： 本发明提供人源化抗TNF单克隆抗体及其用途。 与保守的小鼠嵌合抗体相比，人源化抗TNF单克隆抗体显着降低鼠抗体的免疫原性，同时保留抗体识别抗原的能力。 因此，抗体在临床应用中的安全性得到改善。
-
公开(公告)号：US08658171B2
公开(公告)日：2014-02-25
申请号：US13405144
申请日：2012-02-24
申请人： Baoguo Zhu , Desheng Tao , Bill Nai-Chau Sun , Lee-Hwei King Sun , Ruey Shyan Liou , Cecily Rou-Yun Sun , Qiang Li , Yucai Peng , Jingwei Zhang , Zhenxiang Hu
发明人： Baoguo Zhu , Desheng Tao , Bill Nai-Chau Sun , Lee-Hwei King Sun , Ruey Shyan Liou , Cecily Rou-Yun Sun , Qiang Li , Yucai Peng , Jingwei Zhang , Zhenxiang Hu
IPC分类号： A61K38/00
CPC分类号： C07K16/241 , A61K2039/505 , C07K2317/24 , C07K2317/76 , C07K2317/92 , Y02A50/412
摘要： The present invention provides a humanized anti-TNF monoclonal antibody and the use thereof. The humanized anti-TNF monoclonal antibody significantly reduces the immunogenicity of murine-antibody while retaining the ability of antibody to recognize antigen, compared with conservative mouse chimeric antibody. Therefore, safety of the antibody in clinical applications has been improved.
摘要翻译： 本发明提供人源化抗TNF单克隆抗体及其用途。 与保守的小鼠嵌合抗体相比，人源化抗TNF单克隆抗体显着降低鼠抗体的免疫原性，同时保留抗体识别抗原的能力。 因此，抗体在临床应用中的安全性得到改善。
-
公开(公告)号：US20120116056A1
公开(公告)日：2012-05-10
申请号：US12657004
申请日：2010-01-12
CPC分类号： C07K14/61 , C07K2319/30
摘要： Fc fusion proteins of human growth hormone with good biological activities relative to rhGH on a molar basis are disclosed. The hGH-L-vFc fusion protein comprises hGH, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such hGH-L-vFc fusion proteins exhibit extended or prolonged serum half-life and/or good biological activities relative to that of rhGH on a molar basis, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time.
摘要翻译： 公开了以摩尔计相对于rhGH的具有良好生物活性的人生长激素的Fc融合蛋白。 hGH-L-vFc融合蛋白包含hGH，约20个或更少氨基酸的柔性肽接头和人IgG Fc变体。 Fc变体具有非溶解性质并且显示出最小的不期望的Fc介导的副作用。 还公开了以高表达水平制备或产生这种融合蛋白的方法。 这样的hGH-L-vFc融合蛋白在摩尔基础上相对于rhGH显示出延长的或延长的血清半衰期和/或良好的生物活性，导致改善的药代动力学和药效学，因此在一段时间内将需要更少的注射 。
-
-
-
-
搜索结果
5 条记录 (耗时 0.029 秒)
